Pieris Cost Of Revenue from 2010 to 2024
| PIRS Stock | USD 16.25 0.58 3.45% |
Cost Of Revenue | First Reported 2013-12-31 | Previous Quarter -30 K | Current Value 751 K | Quarterly Volatility 446 M |
Check Pieris Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pieris Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.2 M, Interest Expense of 12.3 M or Selling General Administrative of 13.5 M, as well as many indicators such as Price To Sales Ratio of 0.36, Dividend Yield of 0.0 or PTB Ratio of 0.58. Pieris financial statements analysis is a perfect complement when working with Pieris Pharmaceuticals Valuation or Volatility modules.
Pieris | Cost Of Revenue |
Latest Pieris Pharmaceuticals' Cost Of Revenue Growth Pattern
Below is the plot of the Cost Of Revenue of Pieris Pharmaceuticals over the last few years. Cost of Revenue is found on Pieris Pharmaceuticals income statement and represents the costs associated with goods and services Pieris Pharmaceuticals provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities. It is Pieris Pharmaceuticals' Cost Of Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pieris Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Cost Of Revenue | 10 Years Trend |
|
Cost Of Revenue |
| Timeline |
Pieris Cost Of Revenue Regression Statistics
| Arithmetic Mean | 15,070,778 | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | 141.63 | |
| Mean Deviation | 18,917,085 | |
| Median | 2,368,000 | |
| Standard Deviation | 21,345,326 | |
| Sample Variance | 455.6T | |
| Range | 57.5M | |
| R-Value | 0.53 | |
| Mean Square Error | 354.7T | |
| R-Squared | 0.28 | |
| Significance | 0.04 | |
| Slope | 2,512,595 | |
| Total Sum of Squares | 6378.7T |
Pieris Cost Of Revenue History
About Pieris Pharmaceuticals Financial Statements
Pieris Pharmaceuticals shareholders use historical fundamental indicators, such as Cost Of Revenue, to determine how well the company is positioned to perform in the future. Although Pieris Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Pieris Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Pieris Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Cost Of Revenue | 41.8 M | 21.2 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Pieris Stock Analysis
When running Pieris Pharmaceuticals' price analysis, check to measure Pieris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pieris Pharmaceuticals is operating at the current time. Most of Pieris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pieris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pieris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pieris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.